Insmed Incorporated
$98.60-2.8%YTD-42.3%1Y-8.1%
Mentions · last 7 days
270%
Price updated 5h ago·X counts updated 1d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $INSM, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $INSM.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
What this means for $INSM
Neutral — Biopharmaceutical company with approved ARIKAYCE for refractory lung infections and brensocatib advancing for bronchiectasis; limited read-through from biotechnology macro dynamics to this specific revenue mix.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-17.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-65.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-138%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
25.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-130%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
81.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.76$-0.96+21.1%
Q4 2025Feb 19, 2026$-1.54$-1.07-43.9%
Q3 2025Oct 30, 2025$-1.75$-1.33-31.6%
Q2 2025Aug 7, 2025$-1.70$-1.30-30.8%
Next earningsThu, Aug 6·consensus EPS $-0.69
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$306.0M+229.6%83.8%-65.5%$-0.76$-226.2M
Q4 FY25$263.8M+152.6%83.2%-94.6%$-1.54$-294.2M
Q3 FY25$142.3M+52.4%79.4%-257%$-1.75$-222.2M
Q2 FY25$107.4M+18.9%73.9%-291%$-1.70$-209.1M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$1.7B$1.7B – $1.7B-$2.62-$4.31 – -$1.6615
FY27$2.8B$2.4B – $3.0B$0.34-$0.23 – $0.8615
FY28$3.8B$3.8B – $3.8B$3.07-$0.75 – $6.6818
FY29$4.9B$4.4B – $5.3B$6.56$5.70 – $7.3511
FY30$6.1B$5.5B – $6.7B$10.02$8.70 – $11.229
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-31.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 198.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.785-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KPress release / Reg FDJul 168-K — Item 7.01: Press release / Reg FD
AI summary
3New insider — initial holdingsJun 243
AI summary
S-3ASRAuto-shelf registrationMay 15S-3ASR
AI summary
8-KShareholder voteMay 158-K — Item 5.07: Shareholder vote
AI summary
8-KPress release / Reg FDApr 78-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KPress release / Reg FDMar 238-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KOfficer or director changeFeb 198-K — Item 2.02: Earnings release · Item 5.02: Officer or director change
+ 11 other (5 13Gs · 2 proxys · 1 earnings 8-K · 1 10-Q) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Insmed, Inc. $INSM Stock Holdings Reduced by Bank of Nova ScotiaWatch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSMThis Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 7 · last 7 days